0001209191-20-065185.txt : 20201228
0001209191-20-065185.hdr.sgml : 20201228
20201228164021
ACCESSION NUMBER: 0001209191-20-065185
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201222
FILED AS OF DATE: 20201228
DATE AS OF CHANGE: 20201228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zinda Michael
CENTRAL INDEX KEY: 0001815366
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39335
FILM NUMBER: 201418793
MAIL ADDRESS:
STREET 1: C/O REPARE THERAPEUTICS INC.
STREET 2: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Repare Therapeutics Inc.
CENTRAL INDEX KEY: 0001808158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
BUSINESS PHONE: (857) 412-7018
MAIL ADDRESS:
STREET 1: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-22
0
0001808158
Repare Therapeutics Inc.
RPTX
0001815366
Zinda Michael
C/O REPARE THERAPEUTICS INC.
7210 FREDERICK-BANTING, SUITE 100
ST-LAURENT
A8
H4S 2A1
QUEBEC, CANADA
0
1
0
0
EVP, Chief Science Officer
Common Stock
2020-12-22
4
M
0
15706
1.637
A
100935
D
Common Stock
2020-12-22
4
M
0
25606
2.062
A
126541
D
Common Stock
2020-12-22
4
S
0
1612
34.00
D
124929
D
Common Stock
2020-12-22
4
S
0
39700
33.36
D
85229
D
Common Stock
2020-12-23
4
M
0
1976
1.637
A
87205
D
Common Stock
2020-12-23
4
M
0
4771
2.062
A
91976
D
Common Stock
2020-12-23
4
M
0
9488
2.425
A
101464
D
Common Stock
2020-12-23
4
S
0
12556
33.48
D
88908
D
Common Stock
2020-12-23
4
S
0
3679
34.26
D
85229
D
Common Stock
2020-12-24
4
M
0
432
2.062
A
85661
D
Common Stock
2020-12-24
4
S
0
432
33.14
D
85229
D
Employee Stock Option (right to buy)
1.637
2020-12-22
4
M
0
15706
0.00
D
2027-12-04
Common Stock
15706
13832
D
Employee Stock Option (right to buy)
2.062
2020-12-22
4
M
0
25606
0.00
D
2029-03-29
Common Stock
25606
60101
D
Employee Stock Option (right to buy)
1.637
2020-12-23
4
M
0
1976
0.00
D
2027-12-04
Common Stock
1976
11856
D
Employee Stock Option (right to buy)
2.062
2020-12-23
4
M
0
4771
0.00
D
2029-03-29
Common Stock
4771
55330
D
Employee Stock Option (right to buy)
2.425
2020-12-23
4
M
0
9488
0.00
D
2029-12-16
Common Stock
9488
148466
D
Employee Stock Option (right to buy)
2.062
2020-12-24
4
M
0
432
0.00
D
2029-03-29
Common Stock
432
54898
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3) and (4).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.97 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.61 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.46 inclusive.
Twenty-five percent (25%) of the shares subject to the option vested on June 22, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
Twenty-five percent (25%) of the shares subject to the option vested on March 29, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
Twenty-five percent (25%) of the shares subject to the option vested on December 16, 2020, and one thirty-ninth (1/39th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
/s/ Steve Forte, Attorney-in-Fact
2020-12-28